Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c; Raises FY Revenue outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics (SRPT) PT Raised to $60 at Piper Jaffray
October 26, 2017 4:36 AM EDTPiper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $60.00 (from $55.00) while maintaining a Overweight rating.
Analyst Ed Tenthoff likes the third consecutive beat by Exondys51 on sales and raises his expectations for future sales which drives his PT higher.
... More